CLINICAL TRIALS PROFILE FOR SEEBRI

All Clinical Trials for SEEBRI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02512302 ↗	Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Di	Completed	Sunovion Respiratory Development Inc.	Phase 1	2015-10-01	The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
NCT02622243 ↗	Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge	Completed	University of Saskatchewan	Phase 4	2015-11-01	The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction.
NCT02953041 ↗	Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve	Completed	University of Saskatchewan	Phase 4	2016-10-01	The study will assess the effects of two drugs, glycopyrronium and indacaterol, taken either as monotherapy or in combination, on the methacholine dose-response curve. This will allow for further elucidation of the mechanisms of each drug in human participants.
NCT06282861 ↗	ANTES B+ Clinical Trial	TERMINATED	GlaxoSmithKline	PHASE4	2024-02-29	Current guidelines recommend initial treatment with dual long-acting bronchodilator therapy (LABA-LAMA) in patients with Chronic Obstructive Pulmonary Disease (COPD) of group B (defined by CAT≥10 and none or 1 moderate exacerbation). However, the investigators hypothesize that there is a subgroup of B patients (B+) at a particularly high risk for poor clinical control, characterized by the following: * 1 moderate exacerbation in the previous year * CAT≥10 despite current treatment with LABA -LAMA * Blood eosinophil levels of ≥150 cells/ml the investigators further hypothesize that B+ patients could benefit from triple therapy treatment (LABA-LAMA + Inhaled Corticosteroids). Therefore, the main goal of this clinical trial is to compare the efficacy of Trelegy (triple therapy) in improving clinical control in GOLD B+ patients with chronic obstructive disease when compared to standard double therapy (LABA -LAMA). The clinical control is a validated composite endpoint that includes two domains, the patient's stability, and the impact of the disease. 1028 patients will be randomly allocated to receive either the standard therapy or Trelegy and will be monitored by the investigators for 1 year in 2 on-site visits + 2 remote visits.
NCT06282861 ↗	ANTES B+ Clinical Trial	TERMINATED	Fundacio Privada Mon Clinic Barcelona	PHASE4	2024-02-29	Current guidelines recommend initial treatment with dual long-acting bronchodilator therapy (LABA-LAMA) in patients with Chronic Obstructive Pulmonary Disease (COPD) of group B (defined by CAT≥10 and none or 1 moderate exacerbation). However, the investigators hypothesize that there is a subgroup of B patients (B+) at a particularly high risk for poor clinical control, characterized by the following: * 1 moderate exacerbation in the previous year * CAT≥10 despite current treatment with LABA -LAMA * Blood eosinophil levels of ≥150 cells/ml the investigators further hypothesize that B+ patients could benefit from triple therapy treatment (LABA-LAMA + Inhaled Corticosteroids). Therefore, the main goal of this clinical trial is to compare the efficacy of Trelegy (triple therapy) in improving clinical control in GOLD B+ patients with chronic obstructive disease when compared to standard double therapy (LABA -LAMA). The clinical control is a validated composite endpoint that includes two domains, the patient's stability, and the impact of the disease. 1028 patients will be randomly allocated to receive either the standard therapy or Trelegy and will be monitored by the investigators for 1 year in 2 on-site visits + 2 remote visits.

Clinical Trial Conditions for SEEBRI

Condition Name

Condition Name for SEEBRI
Intervention	Trials
Asthma	2
Chronic Obstructive Pulmonary Disease	1
COPD	1

Condition MeSH

Condition MeSH for SEEBRI
Intervention	Trials
Pulmonary Disease, Chronic Obstructive	2
Lung Diseases, Obstructive	1
Lung Diseases	1

Clinical Trial Locations for SEEBRI

Trials by Country

Trials by Country for SEEBRI
Location	Trials
Canada	2
Spain	1
United Kingdom	1

Clinical Trial Progress for SEEBRI

Clinical Trial Phase

Clinical Trial Phase for SEEBRI
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for SEEBRI
Clinical Trial Phase	Trials
Completed	3
TERMINATED	1

Clinical Trial Sponsors for SEEBRI

Sponsor Name

Sponsor Name for SEEBRI
Sponsor	Trials
University of Saskatchewan	2
GlaxoSmithKline	1
Fundacio Privada Mon Clinic Barcelona	1

Sponsor Type

Sponsor Type for SEEBRI
Sponsor	Trials
Other	3
Industry	2

Seebri (Glycopyrrolate) Clinical Trials Update, Market Analysis, and Sales Projection

Last updated: June 15, 2026

Seebri is a marketed long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD). The drug’s competitive outlook is driven by class-level substitution across LAMA and LAMA/LABA combinations, plus the timing of patent and regulatory exclusivities for the specific Seebri strengths and presentations.

What is Seebri (glycopyrrolate) and what COPD trial endpoints matter for regulators and payers?

Featured snippet: Seebri (glycopyrrolate) is a LAMA indicated for COPD symptom control and reduction of exacerbations; key trial endpoints include trough FEV1, transition dyspnea index (TDI), COPD exacerbation rates, and time-to-first exacerbation.

How are COPD efficacy endpoints typically structured in glycopyrrolate trials?

• Lung function: trough FEV1 (often week 12 to year 1+ in pivotal phase 3)
• Symptoms: TDI using standardized minimum clinically important difference thresholds
• Exacerbations: annualized exacerbation rate and time-to-first exacerbation in longer studies
• Safety: anticholinergic class signals (urinary retention, ocular effects), pneumonia risk (class-dependent in comparators), and overall adverse event (AE) profile

What comparator arms usually determine market positioning?

• Head-to-head or add-on comparisons vs other LAMAs (e.g., tiotropium)
• Combination context vs LAMA/LABA fixed-dose inhalers
• Comparative placebo-controlled arms when differentiation is framed around trough FEV1 and exacerbations

What is the latest clinical trials update for Seebri (glycopyrrolate) in COPD?

No complete, current “latest update” can be produced from the provided information.

How large is the COPD market Seebri competes in, and what share is realistic for a LAMA monotherapy?

Featured snippet: LAMA monotherapy is a shrinking share versus preferred escalation to LAMA/LABA, and later to triple therapy (LAMA/LABA/ICS) in higher-risk patients.

Market structure that drives Seebri outcomes

• Physician treatment ladder: LAMA first for many patients, then escalation based on dyspnea and exacerbation history
• Payer dynamics: formulary placement increasingly favors combination inhalers due to lower net cost per controlled patient and tighter prior authorization edits
• Channel effect: inhaler device familiarity and adherence data influence prescribing, not only molecule efficacy

Where Seebri typically fits

• Patients with moderate COPD and predominant dyspnea without frequent exacerbations
• Patients who are contraindicated for certain combination components
• Transition therapy where payer step edits allow monotherapy access

When does Seebri face exclusivity or generic entry risk and how does that affect projections?

Featured snippet: Accurate launch timing and entry risk depend on Seebri’s specific approved product (strength, device, label) and the associated Orange Book/market authorization exclusivity status.

No complete exclusivity timeline can be produced from the provided information.

What competitive landscape pressures affect glycopyrrolate sales?

Featured snippet: The strongest headwinds are LAMA-to-LAMA and LAMA-to-combo switching, plus broad availability of established COPD inhalers.

Key pressure points

• Class competition: tiotropium/aclidinium/umeclidinium substitutions
• Combination incumbency: entrenched LAMA/LABA brands with better adherence perception and payer incentives
• Triple-therapy migration: for exacerbation-prone patients, triple therapy reduces room for LAMA-only spend
• Device and adherence: the inhaler platform can drive real-world persistence, which shapes payer renewals

What market projection scenarios should be used for Seebri, given COPD class dynamics?

Featured snippet: Projections typically run three paths: base-case continuation of monotherapy share, downside share loss from combination preference, and upside only if Seebri is granted advantageous formulary access or new label differentiation.

Base-case projection logic (class-consistent)

• Stable unit volume if monotherapy access remains unrestricted
• Net revenue pressure from price erosion and trade-down behavior
• Margin pressure increases if payers impose step edits that limit escalation pathways after initial refill patterns are established

Downside projection logic (most common in class)

• Rapid relative growth of LAMA/LABA claims leads to fewer new starts
• Conversion to combination therapy in patients with moderate exacerbations
• Price concessions expand after generic or authorized-duplicate competition appears in the same presentation

Upside projection logic (less common)

• Favorable payer contracting improves share in monotherapy-eligible cohorts
• Demonstrated adherence advantage in real-world evidence supports retention
• Any incremental differentiation in exacerbation reduction in specific subpopulations (if supported by high-quality evidence)

How do you model Seebri revenue exposure by US vs ex-US markets?

No product-specific geography revenue split can be produced from the provided information.

How strong is Seebri’s long-term IP position versus LAMA incumbents?

Featured snippet: Patent strength for COPD inhalers is commonly driven by formulation, device integration, and method-of-use coverage, not just the active ingredient.

No complete IP strength assessment can be produced from the provided information.

Key Takeaways

• Seebri is a COPD LAMA; real-world prescribing is heavily influenced by escalation to LAMA/LABA and later triple therapy.
• Clinical endpoints for COPD differentiation center on trough FEV1, symptom improvement (TDI), and exacerbation reduction.
• For credible sales projections, the critical inputs are current market access, the exact approved product presentation, and the exclusivity/IP timing tied to that presentation.
• Without current trial and regulatory exclusivity data for the specific Seebri product, only class-level projection structure can be stated, not numeric forecasts.

FAQs

1. Is Seebri a LAMA monotherapy or used as part of a combination inhaler strategy for COPD?
2. What COPD trial endpoints most directly influence prescribing decisions for LAMA products like Seebri?
3. What payer rules typically reduce demand for LAMA monotherapy in favor of LAMA/LABA fixed-dose inhalers?
4. How do generic and authorized-duplicate entries usually affect LAMA revenue curves?
5. What real-world factors (inhaler device, persistence, adherence) most impact Seebri sales?

References

1. No sources were provided in the prompt, and no external citations can be reliably generated without a defined input set.